Drug Profile


Alternative Names: ROB 803

Latest Information Update: 09 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OxyPharma
  • Class Acetamides; Disease-modifying antirheumatics; Heterocyclic compounds with 4 or more rings; Small molecules
  • Mechanism of Action Cell differentiation modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis

Most Recent Events

  • 09 Feb 2016 Phase II development is ongoing in European Union, Georgia and Serbia and Montenegro
  • 30 Nov 2009 Efficacy, adverse events and drug interactions data from a phase II trial in Rheumatoid arthritis released by OxyPharma
  • 13 Aug 2009 OxyPharma completes a phase II trial in Rheumatoid arthritis in the EU, Serbia & Georgia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top